non hodgkin lymphoma

Summary

Summary: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Top Publications

  1. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
  2. ncbi Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    B D Cheson
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:1244. 1999
  3. ncbi Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium
    Nathaniel Rothman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet Oncol 7:27-38. 2006
  4. ncbi Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
    Gary M Clifford
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 97:425-32. 2005
  5. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
  6. ncbi Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4643-51. 2005
  7. ncbi Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies
    Lennart Hardell
    Department of Oncology, Orebro University Hospital, Sweden
    Leuk Lymphoma 43:1043-9. 2002
  8. pmc Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma
    Qing Lan
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, MSC 7240, 6120 Executive Blvd, EPS 8109, Bethesda, MD 20892 7240, USA
    Blood 107:4101-8. 2006
  9. ncbi Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma
    Christine F Skibola
    Division of Environmental Health Sciences, School of Public Health, 140 Earl Warren Hall, University of California, Berkeley, CA 94720 7360, USA
    Cancer Epidemiol Biomarkers Prev 13:779-86. 2004
  10. ncbi Non-Hodgkin lymphoma: diagnosis and treatment
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1087-97. 2005

Detail Information

Publications346 found, 100 shown here

  1. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  2. ncbi Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    B D Cheson
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:1244. 1999
    ..We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available...
  3. ncbi Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium
    Nathaniel Rothman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Lancet Oncol 7:27-38. 2006
    ..We aimed to test this hypothesis using previously unpublished data from eight European, Canadian, and US case-control studies of the International Lymphoma Epidemiology Consortium (InterLymph)...
  4. ncbi Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
    Gary M Clifford
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    J Natl Cancer Inst 97:425-32. 2005
    ....
  5. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  6. ncbi Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
    Heiko Schoder
    Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4643-51. 2005
    ..18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease...
  7. ncbi Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies
    Lennart Hardell
    Department of Oncology, Orebro University Hospital, Sweden
    Leuk Lymphoma 43:1043-9. 2002
    ..However, in multivariate analyses the only significantly increased risk was for a heterogeneous category of other herbicides than above...
  8. pmc Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma
    Qing Lan
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, MSC 7240, 6120 Executive Blvd, EPS 8109, Bethesda, MD 20892 7240, USA
    Blood 107:4101-8. 2006
    ..84; 95% CI = 1.79-8.22; P < .001). Further, the IL10 and IL4 SNP associations remained significant after adjusting for multiple comparisons. These results suggest that SNPs in Th2 cytokine genes may be associated with risk of NHL...
  9. ncbi Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma
    Christine F Skibola
    Division of Environmental Health Sciences, School of Public Health, 140 Earl Warren Hall, University of California, Berkeley, CA 94720 7360, USA
    Cancer Epidemiol Biomarkers Prev 13:779-86. 2004
    ....
  10. ncbi Non-Hodgkin lymphoma: diagnosis and treatment
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1087-97. 2005
    ..Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies...
  11. ncbi Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium
    Anne Kricker
    School of Public Health, University of Sydney, Sydney, New South Wales, Australia
    Int J Cancer 122:144-54. 2008
    ..Increased recreational sun exposure may protect against NHL...
  12. ncbi Persistent organochlorine chemicals in plasma and risk of non-Hodgkin's lymphoma
    Anneclaire J De Roos
    Fred Hutchinson Cancer Research Center and University of Washington Department of Epidemiology, Seattle, Washington 98109 1024, USA
    Cancer Res 65:11214-26. 2005
    ..02-1.79). Our results add to existing literature, which suggests that exposure to organochlorines contributes to non-Hodgkin's lymphoma risk; these risks were most apparent for certain PCBs and furans...
  13. ncbi Polychlorinated biphenyl levels in peripheral blood and non-Hodgkin's lymphoma: a report from three cohorts
    Lawrence S Engel
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 67:5545-52. 2007
    ..The results from these three cohorts suggest that concentrations of certain PCBs in blood are associated with increased risk of NHL...
  14. ncbi Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
    Elizabeth C Moser
    European Organization for Research on Treatment of Cancer EORTC Data Center, Brussels, Belgium
    Blood 107:2912-9. 2006
    ..In conclusion, patients are at long-term high risk of chronic heart failure after NHL treatment and need therefore life-long monitoring. In contrast, risk of coronary artery disease appeared more age dependent than treatment related...
  15. ncbi Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma
    Matthew S Forrest
    Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720 7360, USA
    Br J Haematol 134:180-3. 2006
    ..67, 95% CI 0.45-0.99). These results suggest that variation in innate immune genes may alter NHL susceptibility...
  16. pmc Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:4455-63. 2007
    ....
  17. pmc Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)
    Lindsay M Morton
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Blood 110:695-708. 2007
    ....
  18. ncbi Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Leuk Lymphoma 44:2069-76. 2003
    ..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...
  19. ncbi Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study
    C Haioun
    Hopital Henri Mondor, Assistance Publique Hopitaux de Paris AP HP, Creteil, France
    J Clin Oncol 18:3025-30. 2000
    ....
  20. ncbi Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial
    Maurizio Martelli
    Department of Cellular Biotechnology and Hematology, University La Sapienza of Rome, Italy
    J Clin Oncol 21:1255-62. 2003
    ..To evaluate the role of early intensification with high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) as front-line chemotherapy for patients with high-risk, histologically aggressive non-Hodgkin's lymphoma (NHL)...
  21. ncbi Non-hodgkin's lymphoma and agricultural use of the insecticide lindane
    A Blair
    Occupational Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892 7364, USA
    Am J Ind Med 33:82-7. 1998
    ..5 to 1.2 and 1.3, respectively. Lindane does not appear to be a major etiologic factor in the development of non-Hodgkin's's lymphoma, although a small role cannot be ruled out...
  22. ncbi Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    P McLaughlin
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2825-33. 1998
    ..It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies...
  23. ncbi The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
    Jonathan D Tward
    Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah 84112 5560, USA
    Cancer 107:108-15. 2006
    ..Survivors of non-Hodgkin lymphoma (NHL) are at increased risk for developing secondary malignancies. For the current study, the authors quantitated this risk in a group of NHL survivors over 30 years of follow-up...
  24. ncbi Agricultural risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma
    J C Schroeder
    Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
    Epidemiology 12:701-9. 2001
    ..Results suggest that non-Hodgkin's lymphoma classification based on the t(14;18) translocation is of value in etiologic research...
  25. ncbi High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
    Harry C Schouten
    Department of Internal Medicine, University Hospital Maastricht, The Netherlands
    J Clin Oncol 21:3918-27. 2003
    ....
  26. ncbi Soft-tissue sarcoma and non-Hodgkin's lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels
    J F Viel
    Department of Public Health, Faculty of Medicine, Besancon, France
    Am J Epidemiol 152:13-9. 2000
    ..g., a case-control study in which dioxins are measured in biologic tissues) before clusters of soft-tissue sarcoma and non-Hodgkin's lymphoma are ascribed to dioxin released by the municipal solid waste incinerator...
  27. ncbi VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
    G Santini
    Department of Haematology, San Martino Hospital, Genova, Italy
    J Clin Oncol 16:2796-802. 1998
    ....
  28. ncbi Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia)
    Lin Fritschi
    School of Population Health, University of Western Australia, Perth, Australia
    Cancer Causes Control 16:599-607. 2005
    ..We aimed to use accurate means to assess occupational exposures to solvents, metals, organic dusts and polychlorinated biphenyls (PCBs) in a case-control study...
  29. ncbi Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:1103-8. 2005
    ..The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC)...
  30. ncbi Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
    T Nousiainen
    Department of Medicine, Kuopio University Hospital and University of Kuopio, Finland
    Eur J Haematol 62:135-41. 1999
    ..On the other hand, our study suggests that natriuretic peptides are useful in the detection of subclinical left ventricular dysfunction in patients receiving doxorubicin therapy...
  31. ncbi Occupational exposure to solvents and the risk of lymphomas
    Lucia Miligi
    Istituto Toscano Tumori, Unit of Environmental and Occupational Epidemiology, Centre for Study and Prevention of Cancer, Via di S Salvi 12, 50135 Florence, Italy
    Epidemiology 17:552-61. 2006
    ..The present investigation aimed to evaluate the association between exposure to solvents and lymphomas (Hodgkin and non-Hodgkin) in a large population-based, multicenter, case-control study in Italy...
  32. pmc Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry
    K A Gurney
    Leukaemia Research Fund Centre for Clinical Epidemiology, University of Leeds, UK
    Br J Cancer 79:1929-34. 1999
    ..Overall, the incidence of gastrointestinal NHL significantly increased by 2.7% per annum and was limited to the population aged over 50 years in this series...
  33. ncbi Skin cancer and non-Hodgkin's lymphoma as second malignancies. markers of impaired immune function?
    K Hemminki
    Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    Eur J Cancer 39:223-9. 2003
    ..0 for Hodgkin's disease; 3.6 for UADT as the first site). The high, and after certain sites, very high risks of second skin cancer and non-Hodgkin's lymphoma suggest that immune suppression may be a contributory mechanism...
  34. ncbi Cancer risk in people infected with human immunodeficiency virus in the United States
    Eric A Engels
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    Int J Cancer 123:187-94. 2008
    ..These trends have led to a shift in the spectrum of cancer among HIV-infected persons...
  35. pmc Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:3161-9. 2008
    ....
  36. ncbi Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment
    T A Davis
    Stanford University, CA, USA
    J Clin Oncol 18:3135-43. 2000
    ....
  37. ncbi Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study
    Elizabeth C Moser
    EORTC Data Centre, Brussels, Belgium
    Haematologica 91:1481-8. 2006
    ..Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments...
  38. ncbi Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
    G Jerusalem
    Department of Medicine, University of Liege, Belgium
    Ann Oncol 12:825-30. 2001
    ..We undertook this study to determine factors influencing the detection of lesions by PET in low-grade NHL and to evaluate the utility of PET in this indication...
  39. ncbi Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma
    Severin Daum
    Department of Medicine I, Universitatsklinikum Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    J Clin Oncol 21:2740-6. 2003
    ..Intestinal non-Hodgkin's lymphomas are not well characterized. We therefore studied prospectively their clinical features and response to standardized therapy...
  40. ncbi Ultraviolet radiation exposure and risk of malignant lymphomas
    Karin Ekstrom Smedby
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE 171 77 Stockholm, Sweden
    J Natl Cancer Inst 97:199-209. 2005
    ..One hypothesis holds that exposure to ultraviolet (UV) radiation increases lymphoma risk. We tested this hypothesis in a population-based case-control study in Denmark and Sweden...
  41. ncbi Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health
    H H McDuffie
    Centre for Agricultural Medicine, University of Saskatchewan, Saskatoon, Saskatchewan
    Cancer Epidemiol Biomarkers Prev 10:1155-63. 2001
    ..We concluded that NHL was associated with specific pesticides after adjustment for other independent predictors...
  42. ncbi Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications
    Christina A Clarke
    Northern California Cancer Center, Union City, California, USA
    Cancer Epidemiol Biomarkers Prev 13:138-43. 2004
    ..Thus, overall NHL incidence and survival statistics from the early 1990s are probably accurate, but subtype-specific statistics could be substantially biased, especially because of high (15-20%) proportions of unclassified lymphomas...
  43. ncbi Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA
    Clin Cancer Res 9:5866-73. 2003
    ..The purpose of this work was to study the effect(s) of neutrophils on the in vivo antitumor activity of rituximab...
  44. pmc Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms
    E V Willett
    Epidemiology and Genetics Unit, Department of Health Sciences, Seebohm Rowntree Building, University of York, UK
    Br J Cancer 93:811-6. 2005
    ..5-1.0) and increased with LEP -2548GA (OR = 1.3, 95% CI 1.0-1.7) and -2548AA (OR = 1.4, 95% CI 1.0-1.9), particularly for follicular lymphoma. These genetic findings, which were independent of BMI, were stronger for men than women...
  45. ncbi Non-Hodgkin lymphoma
    Linda S Evans
    Weston Park Hospital, S10 2SJ, Sheffield, UK
    Lancet 362:139-46. 2003
    ....
  46. pmc Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy
    B Vaughan Hudson
    Department of Haematology, University College London School of Medicine, UK
    Br J Cancer 69:1088-93. 1994
    ....
  47. ncbi Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was
    Sven Sandin
    Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
    Cancer Epidemiol Biomarkers Prev 15:1295-300. 2006
    ..Insights into the descriptive epidemiology of NHL may shed light upon its elusive etiology...
  48. ncbi Pesticide exposures in children with non-Hodgkin lymphoma
    J D Buckley
    Department of Preventive Medicine, University of Southern California, Los Angeles, USA
    Cancer 89:2315-21. 2000
    ..However, to the authors' knowledge, data regarding pesticide exposures in children diagnosed with NHL have been lacking...
  49. ncbi Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project
    T Rudiger
    University of Wurzburg, Germany
    Ann Oncol 13:140-9. 2002
    ....
  50. ncbi Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy
    J M Pluda
    National Cancer Institute, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
    Ann Intern Med 113:276-82. 1990
    ..As improved therapies for the treatment of HIV infection and its complications result in prolonged survival, non-Hodgkin lymphoma may become an increasingly significant problem...
  51. ncbi Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy
    Renato Talamini
    Servizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
    Int J Cancer 110:380-5. 2004
    ..In conclusion, HCV infection was associated with an increase in NHL risk, and the fraction of NHL cases attributable to HCV was 12.4% (range 6.3-18.5%)...
  52. ncbi The non-Hodgkin lymphomas: a review of the epidemiologic literature
    Dominik D Alexander
    Exponent Health Sciences Group, Exponent, Inc, Wood Dale, IL, USA
    Int J Cancer 120:1-39. 2007
    ..The extent to which the etiology of NHL types may differ is important to resolve in ongoing and future studies...
  53. ncbi Conservative management of gastric lymphoma: the treatment option of choice
    Wolf Peter Schmidt
    Department of Haematology, Allgemeines Krankenhaus St Georg, Hamburg, Germany
    Leuk Lymphoma 45:1847-52. 2004
    ..Survival was similar compared to patients initially treated with surgery. To avoid long-term sequelae after gastric resection, primary CHT is recommended as standard initial treatment in localized gastric lymphoma...
  54. ncbi Antidepressant medication use and non-Hodgkin's lymphoma risk: no association
    Saira Bahl
    Division of Preventive Oncology, Cancer Care Ontario, Toronto, Ontario, Canada
    Am J Epidemiol 160:566-75. 2004
    ..These findings do not support an increased risk of non-Hodgkin's lymphoma with antidepressant medication use...
  55. ncbi Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends
    Shotaro Nakamura
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Cancer 97:2462-73. 2003
    ..This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients..
  56. ncbi Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma
    Eleanor V Willett
    Department of Health Sciences, Leukaemia Research Fund Epidemiology and Genetics Unit, Seebohm Rowntree Building, University of York, York YO105DD, UK
    Cancer Causes Control 15:771-80. 2004
    ..The aim was to test whether non-Hodgkin lymphoma (NHL) is associated with smoking or alcohol...
  57. ncbi The risk of lymphoma development in autoimmune diseases: a meta-analysis
    Elias Zintzaras
    Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece
    Arch Intern Med 165:2337-44. 2005
    ....
  58. ncbi Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
    Bing He
    Departments of Pathology and Laboratory Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Immunol 172:3268-79. 2004
    ..Thus, neutralization of BAFF and APRIL by soluble TACI and BCMA decoy receptors could be useful to dampen the accumulation of malignant B cells in NHL patients...
  59. ncbi Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma
    Y Tsutsumi
    Department of Internal Medicine, Hakodate Municipal Hospital 1 10 1, 041 0821 Minato cho, Hakodate, Japan
    Ann Hematol 83:58-60. 2004
    ..Lamivudine prophylaxis was effective, at least when rituximab was given to an HBsAg-positive patient with non-Hodgkin's lymphoma...
  60. pmc Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women
    L M Morton
    Department of Epidemiology and Public Health, Yale University School of Medicine, 129 Church Street, Suite 700, New Haven, CT 06510, USA
    Br J Cancer 89:2087-92. 2003
    ..This research highlights the importance of distinguishing between NHL subtypes in future research on the aetiology of NHL...
  61. ncbi Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
    N Niitsu
    First Department of Internal Medicine, Toho University School of Medicine, Tokyo Research Institute, Saitama Cancer Center, Saitama
    Blood 97:1202-10. 2001
    ..Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma...
  62. ncbi Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)
    Ikuko Kato
    Department of Environmental Medicine, New York University of School of Medicine, New York, NY, USA
    Cancer Causes Control 13:965-74. 2002
    ..To examine whether exposures to anti-inflammatory and non-narcotic analgesic drugs are associated with risk of non-Hodgkin's lymphoma (NHL)...
  63. ncbi Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma
    N Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Sagamihara shi, Kanagawa, Japan
    Leukemia 17:196-202. 2003
    ..The nm23-H1 protein appears to be intimately related to biological aggressiveness of lymphoma and, therefore, might be a molecular target of NHL treatment...
  64. ncbi Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    T Kewalramani
    Department of Medicine, Lymphoma and Hematology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 32:673-9. 2003
    ....
  65. ncbi Agricultural use of organophosphate pesticides and the risk of non-Hodgkin's lymphoma among male farmers (United States)
    B L Waddell
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Causes Control 12:509-17. 2001
    ..Associations, however, between reported use of diazinon and NHL, particularly diffuse and small lymphocytic lymphoma, among subjects providing direct interviews are not easily discounted...
  66. ncbi Cohort mortality study of Philadelphia firefighters
    D Baris
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892, USA
    Am J Ind Med 39:463-76. 2001
    ..Fire fighters are exposed to a wide variety of toxic chemicals. Previous studies have reported excess risk of some cancers but have been limited by small numbers or little information on employment characteristics...
  67. ncbi Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Am J Epidemiol 156:527-35. 2002
    ..The opposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance finding but, if confirmed, would suggest different etiologies for these malignancies...
  68. ncbi Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
    Greg L Plosker
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:803-43. 2003
    ..g. bronchospasm, hypotension). These reactions are usually reversible with appropriate interventions and supportive care but there have been rare reports of fatalities...
  69. ncbi Organochlorines and risk of non-Hodgkin lymphoma
    John J Spinelli
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Int J Cancer 121:2767-75. 2007
    ..lowest quartile OR = 2.68, 95% confidence interval = 1.69-4.24). Our results provide further evidence that organochlorines contribute to NHL risk...
  70. pmc Haematopoietic cancer and medical history: a multicentre case control study
    P Vineis
    Unit of Cancer Epidemiology, Ospedale S Giovanni, Torino, Italy
    J Epidemiol Community Health 54:431-6. 2000
    ..Other associations (diabetes, tonsillectomy, autoimmune diseases) have been inconsistently reported...
  71. ncbi Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study
    N A Willich
    Department of Radiotherapy, University of Munster, Munster, Germany
    Int J Radiat Oncol Biol Phys 46:895-901. 2000
    ..Aim of study was the further standardization of operative and conservative treatment modalities...
  72. ncbi FDG-PET/CT in re-staging of patients with lymphoma
    L S Freudenberg
    Clinic and Policlinic for Nuclear Medicine, University of Essen, Essen, Germany
    Eur J Nucl Med Mol Imaging 31:325-9. 2004
    ..02) and has additional benefit over FDG-PET alone due to exact anatomical localisation. We conclude that FDG-PET/CT imaging is accurate in re-staging lymphoma and offers advantages over separate FDG-PET and CT imaging...
  73. ncbi ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
    Felix Reyes
    Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Creteil, France
    N Engl J Med 352:1197-205. 2005
    ..To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone...
  74. ncbi Prognostic factors in non-Hodgkin lymphoma stage I treated with radiotherapy
    H Hagberg
    Department of Oncology, University of Uppsala, Sweden
    Acta Oncol 28:45-50. 1989
    ..e. highgrade NHL. This study indicates that large nodal lymphomas and some extranodal sites belong to this group...
  75. pmc Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma
    R A Nelson
    Department of Preventive Medicine, School of Medicine, University of Southern California, Los Angeles 90033, USA
    Br J Cancer 76:1532-7. 1997
    ..8, 95% confidence limits = 1.2-28.4); among these drugs, cocaine use appeared to account for the elevated risk of NHL among men based on multivariable analyses...
  76. ncbi Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
    Mark P Purdue
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892 7240, USA
    Carcinogenesis 28:704-12. 2007
    ..06, 95% CI=0.88-4.83; trend test, P=0.02). Our findings offer further evidence that variation in the IL10 and TNF loci influences NHL risk. Additional studies are needed to clarify the genetic and biologic basis for these relationships...
  77. pmc Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
    Karin Ekstrom Smedby
    Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Blood 111:4029-38. 2008
    ..Thus, specific autoimmune disorders are associated with NHL risk beyond the development of rare NHL subtypes in affected organs. The pattern of associations with NHL subtypes may harbor clues to lymphomagenesis...
  78. pmc Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness
    D N Aryee
    Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
    Br J Cancer 74:1693-8. 1996
    ..No mutation was found by this screening. Our results suggest a role for nm23-H1 expression in the disease aggressiveness of lymphomas...
  79. pmc Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma
    P Brennan
    International Agency for Research on Cancer, 69008 Lyon, France
    Br J Cancer 93:159-66. 2005
    ..Bidirectional effects for several cancer sites of potential viral origin argue strongly for a role for immune suppression in NHL...
  80. ncbi Sun exposure may protect against non-Hodgkin lymphoma: a case-control study
    Ann Maree Hughes
    School of Public Health, The University of Sydney, Australia
    Int J Cancer 112:865-71. 2004
    ..Increasing evidence that vitamin D may protect against cancer makes UV-mediated synthesis of vitamin D a plausible mechanism whereby sun exposure might protect against NHL...
  81. pmc A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma
    C Burton
    University College London and CRUK Clinical Trials Centre, 222 Euston Road, London NW1 2DA, UK
    Br J Cancer 94:806-13. 2006
    ..There was no significant difference in the failure-free, progression-free or overall survival with the addition of G-CSF...
  82. ncbi The epidemiology of non-Hodgkin's lymphoma
    Susan G Fisher
    Division of Epidemiology, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 644, New York 14642, USA
    Oncogene 23:6524-34. 2004
    ..We must build on our current knowledge regarding the etiology of NHL in order that prevention, treatment, and ultimately, cure of this malignancy becomes a reality...
  83. ncbi Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark
    Blood 98:3406-12. 2001
    ..After starting HAART, patients with insufficient immunologic and virologic responses were at highest risk of NHL...
  84. ncbi Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma
    Olaf Weingart
    Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:E1. 2007
  85. ncbi Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma
    E Hardell
    Department of Oncology, Orebro Medical Center, Sweden
    Leuk Lymphoma 42:619-29. 2001
    ..Also for the "sum of immunotoxic PCBs" increased risk was found in that group (OR=6.4, CI=1.9-24). Subdivision of NHL in histological types yielded highest risks for low-grade B-cell NHL...
  86. ncbi Ultraviolet radiation and incidence of non-Hodgkin's lymphoma among Hispanics in the United States
    Shasa Hu
    Department of Dermatology and Cutaneous Surgery, Sylvester Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
    Cancer Epidemiol Biomarkers Prev 13:59-64. 2004
    ..Additional studies should be conducted to clarify whether sunlight exposure contributes to the development of NHL...
  87. ncbi Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database
    Andrea Altieri
    Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany
    Blood 106:668-72. 2005
    ..The patterns of risks in parents and siblings support the hypothesis of an autosomal-dominant component for diffuse large B-cell NHL and a recessive one for follicular NHL...
  88. ncbi Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing
    Kristen H Taylor
    Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri Columbia, Columbia, Missouri, USA
    Cancer Res 67:8511-8. 2007
    ..This new generation of methylome sequencing will provide digital profiles of aberrant DNA methylation for individual human cancers and offers a robust method for the epigenetic classification of tumor subtypes...
  89. ncbi Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    I F Khouri
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2817-24. 1998
    ....
  90. ncbi Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma
    Osnat Bairey
    Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
    Eur J Haematol 76:384-91. 2006
    ....
  91. ncbi A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    Blood 102:1606-12. 2003
    ..This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016)...
  92. ncbi Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials
    Gregory A Wiseman
    Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Nucl Med 44:465-74. 2003
    ..Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data...
  93. ncbi Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe
    Peter Adamson
    Epidemiology and Genetics Unit, Department of Health Sciences, University of York, Seebohm Rowntree Building, Alcuin Area 3, York YO10 5DD, UK
    Eur J Cancer 43:391-401. 2007
    ..Overall, there are increases in the numbers of NHL registrations made with a corresponding decrease in HL. In recent history, however, there is a suggestion that the rate of increase is less and stable...
  94. ncbi Association of HLA alleles with non-Hodgkin's lymphoma in Korean population
    Hee Baeg Choi
    Catholic Hemopoietic Stem Cell Bank, Department of Microbiology, College of Medicine, The Catholic University of Korea, 505 Banpo Dong, Seocho Ku, Seoul, South Korea
    Int J Hematol 87:203-9. 2008
    ..Also, the B51-DRB1*09-DQB1*03 haplotype was significantly increased in the patients with NHL. These results suggest that some genes in HLA-B*51-DRB1*09-DQB1*03 haplotype may contribute to NHL susceptibility in the Korean population...
  95. ncbi [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]
    Alma Halilbasic
    Univerzitetski centar Tuzla, Trnovac
    Med Arh 60:78-83. 2006
    ..It especially illustrates the post war period from 1998 to 2002...
  96. ncbi Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
    Marc Andre
    Hematology Department, Centre Hospitalier Notre Dame et Reine Fabiola, Grand Rue 3, 6000 Charleroi, Belgium, E mail
    Blood 103:1222-8. 2004
    ..9; P <.001). With a long follow-up, the ACVBP regimen was highly effective for the treatment of aggressive NHL. Increases occurred in secondary MDS/AML and in lung cancer among men...
  97. pmc Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium
    Christine F Skibola
    237A Hildebrand Hall, School of Public Health, University of California, Berkeley, Berkeley, CA 94720 7360, USA
    Am J Epidemiol 171:267-76. 2010
    ..04). These findings strengthen previous results for DLBCL and the LTA 252A>G/TNF -308A locus and provide robust evidence that these TNF/LTA gene variants, or others in linkage disequilibrium, are involved in NHL etiology...
  98. ncbi Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma
    J F Modiano
    Leukemia 21:184-7. 2007
  99. pmc Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis
    J Askling
    Clinical Epidemiology Unit M9 01, Department of Medicine, Karolinska University Hospital Solna, SE 171 77 Stockholm, Sweden
    Ann Rheum Dis 64:1765-8. 2005
    ..Polymyalgia rheumatica (PMR) and temporal arteritis (giant cell arteritis, GCA) are common inflammatory conditions treated with steroids as single immunosuppressive therapy, but data on lymphoma risk in GCA/PMR are limited...
  100. ncbi Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection
    Michele Spina
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 38:142-4. 2004
    ..4 for HIV-infected patients vs. 1 for HIV-negative patients; P=.24). Therefore, the achievement of complete remission should be the main goal in the treatment of patients with HIV-NHL...
  101. ncbi Interstitial pneumonitis related to rituximab therapy
    Catherine Burton
    N Engl J Med 348:2690-1; discussion 2690-1. 2003

Research Grants75

  1. Parental age at birth and risk of adult-onset cancer in female offspring
    Yani Lu; Fiscal Year: 2013
    ..The long-term goal of the research is to explore biomarkers that link parental age and cancer risk to clarify etiology, and thus provide potential targets for prevention. ..
  2. Optimization of adoptive immunotherapy with autologous CD20-specific T cells
    Brian Till; Fiscal Year: 2013
    ....
  3. Non-Hodgkin lymphoma in women: reproductive, hormonal and genetic factors
    Paige M Bracci; Fiscal Year: 2011
    ....
  4. GB Virus C and Non-Hodgkins Lymphoma Risk and Prognosis
    Jack T Stapleton; Fiscal Year: 2013
    ..Regardless of the results obtained, this study has the potential to have a great impact on public health regarding transfusion medicine, and potentially in the clinical management of NHL patients. ..
  5. Murine Models for Mantle Cell Lymphoma: The role of tumor initiating cells (TIC)
    Richard J Ford; Fiscal Year: 2010
    ....
  6. Genetics of risk of chemotherapy-induced cardiotoxicity in cancer survivors
    Peter Demant; Fiscal Year: 2013
    ..This will have strong prospects to uncover novel pathways influencing ACT and open the way for definition of individual ACT pathogenesis in mice and humans. ..
  7. The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation
    Jack T Stapleton; Fiscal Year: 2013
    ..Identification and characterization of this HCV E2 - lymphocyte interaction may contribute to the development of novel therapeutic and/or vaccine approaches to HCV, and potentially to related viruses within the Flaviviridae. ..
  8. Vitamin D and Non-Hodgkin Lymphoma Prognosis
    Jennifer L Kelly; Fiscal Year: 2012
    ..There are an estimated 20,000 annual NHL deaths, though epidemiology of NHL prognosis remains poorly understood. Vitamin D is a modifiable lifestyle factor, and closer evaluation of its role in NHL prognosis is warranted. ..
  9. Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
    Sophia Wang; Fiscal Year: 2013
    ..Public health relevance: successful completion of this study will contribute to the understanding of host genetic variation and tumor markers in NHL survival. ..
  10. Trial of mesna to prevent doxorubicin-induced plasma protein oxidation and TNFa r
    Jeffrey A Moscow; Fiscal Year: 2012
    ....
  11. Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
    ROBERT T STRIKER; Fiscal Year: 2011
    ..This database will catalog VA strains of HCV that need to be targeted by antivirals like cyclophilin inhibitors as well as others that are currently being investigated mostly outside the VA. ..
  12. Alpha Radioimmunotherapy for Lymphoma Treatment
    BRENDA MARIE SANDMAIER; Fiscal Year: 2013
    ..We anticipate that the information from these studies will allow rapid translation of the optimized promising RIT strategy using 211At-anti-CD45 MAb into our clinical RIT HCT program for NHL. ..
  13. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer. ..
  14. Targeted therapy of pancreatic cancer with in vivo radionuclide generator
    Ekaterina Dadachova; Fiscal Year: 2012
    ..If successful, this approach offers the possibility of cure for PCa. ..
  15. Genetic Susceptibility to Non-Hodgkins Lymphoma
    Christine F Skibola; Fiscal Year: 2012
    ....
  16. Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma
    FRANK W MARCOUX; Fiscal Year: 2013
    ..In our estimation, this therapeutics could have an impact on more than 100,000 new cancer cases that are diagnosed each year in the U.S. ..
  17. Immune complexes: origins and effects in HCV infection
    Lynn B Dustin; Fiscal Year: 2013
    ..Our group is uniquely qualified to perform this study because of our expertise in HCV immunology and virology, and our ready access to viruses, viral proteins, and patients for study. ! ..
  18. Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
    SARO ARMENIAN; Fiscal Year: 2013
    ....
  19. CD20-targeted IL-15 immunotherapeutic for B-cell malignancies
    Hing C Wong; Fiscal Year: 2012
    ....
  20. Functional analysis of leukemic CREBBP mutations
    Charles G Mullighan; Fiscal Year: 2013
    ..The translational impact of the results will be to enhance the knowledge-driven therapeutic use of glucocorticoids and HDACi to treat leukemia based on tumor cell genotype. ..
  21. Elucidating the Chemistry and Biology of Nucleic Acid Cytidine Deaminases in HIV
    RAHUL MANU KOHLI; Fiscal Year: 2013
    ..abstract_text> ..
  22. Cancer risk after renal transplant in autoimmune disease
    Rosalind Ramsey-Goldman; Fiscal Year: 2013
    ....
  23. The Role of NPM-ALK Signaling in Tumor Cell Metabolism
    SCOTT RP MCDONNELL; Fiscal Year: 2012
    ..The goal of this project is to determine how cells that express NPM- ALK proliferate and survive in order to identify new strategies for treatment. ..
  24. Molecular Epidemiology of NHL and CLL
    James R Cerhan; Fiscal Year: 2012
    ....
  25. 1st International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymp
    Monika Metzger; Fiscal Year: 2011
    ....
  26. Pesticide Exposure and Childhood Cancer Study
    Beate R Ritz; Fiscal Year: 2012
    ..California children diagnosed with certain cancers (acute myeloid leukemia, acute lymphoblastic leukemia, non Hodgkin lymphoma, astrocytoma, primitive neuroectodermal tumors, Wilms tumor, soft tissue sarcomas) and population-based ..
  27. A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
    Brenda M Birmann; Fiscal Year: 2013
    ....
  28. CTCL immunobiology: lessons from alemtuzumab
    RACHAEL ANN CLARK; Fiscal Year: 2013
    ..Our work will also provide critical insights into human immunobiology, providing the first evidence in humans that TCM are migratory, TEM are nonmigratory, and that TEM can provide immune protection of the skin in the absence of TCM. ..
  29. Resequencing and Functional Studies to Identify Causal Gene Variants of Lymphoma
    Christine F Skibola; Fiscal Year: 2013
    ..Thus, the identification of causal gene variants in this region for lymphoma may also prove helpful in understanding other diseases sharing common susceptibility loci. ..
  30. Detection of Light Chain Restriction in non-Hodgkin Lymphoma by a Novel RNA In Si
    Xiao Jun Ma; Fiscal Year: 2012
    ..Detection of restricted immunoglobulin light chain expression is a molecular ancillary tool to resolve ambiguous lymphoproliferative disorders. The proposed product based on RNAscope will provide superior sensitivity to current methods. ..
  31. Engineering Stem Cell Niches to Guide Differentiation
    DANIELLE A TSOU; Fiscal Year: 2011
    ..The hematopoietic differentiation pathways in the murine system have been established, and a specific ESC line will allow simultaneous monitoring of mesoderm and hematopoietic differentiation. ..
  32. Proteomic analysis of api2-MALT1 positive gastric MALT lymphoma
    Kojo S J Elenitoba-Johnson; Fiscal Year: 2013
    ....
  33. Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma Survival
    ANDREW M contact EVENS; Fiscal Year: 2010
    ..The results will provide new insights into improved disease prognostication, and ultimately lead to better treatment selection. ..
  34. Lifestyle Factors and Lymphoma: An Asia Cohort Consortium Pooling Project
    Brian C H Chiu; Fiscal Year: 2013
    ..abstract_text> ..
  35. Role of MLL2 Gene Inactivation in B cell Non Hodgkin Lymphoma
    Laura Pasqualucci; Fiscal Year: 2013
    ....
  36. Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
    RICHARD M LONGNECKER; Fiscal Year: 2012
    ..Our specific goals are to identify drugs that target EBV latent infections and EBV-associated lymphomas that occur in the human host by using inhibitors of cell proteins targeted by EBV. ..
  37. The Ohio State Blood and Marrow Transplant Reseach Consortium
    Steven M Devine; Fiscal Year: 2013
    ..We seek to test new agents following AHCT in patients with DLCL to determine if we can lower the risk of relapse and improve the lives of these patients. ..
  38. Molecular Epidemiology of Nutrition and Cancer in the Multiethnic Cohort Study
    Laurence N Kolonel; Fiscal Year: 2010
    ..This P01 should add substantially to knowledge of cancer etiology, as well as to an understanding of the basis for ethnic/racial disparities in cancer occurrence. ..
  39. TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS
    Jacqueline E Payton; Fiscal Year: 2013
    ..abstract_text> ..
  40. Beyond GWAS: the next 10 years of InterLymph
    Wendy Cozen; Fiscal Year: 2011
    ....
  41. City of Hope Lymphoma SPORE
    Stephen J Forman; Fiscal Year: 2013
    ..This Lymphoma SPORE will also support a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma. ..
  42. Regulation of B cell development by the proto-oncogene LRF/Pokemon
    Takahiro Maeda; Fiscal Year: 2013
    ....
  43. Host Defense Regulation and Viral Oncogenesis
    Glen N Barber; Fiscal Year: 2013
    ..PROJECT II, William Harrington, Jr., M.D.: Host Defense regulation by HTLV-1. PROJECT III, Enrique Mesri, Ph.D.: HHV8 (KSHV)-Mediated Regulation of Host Defense. ..
  44. The Pathogenesis of Autoimmunity in Hepatitis C Virus Infection
    Edgar D Charles; Fiscal Year: 2012
    ..Relevance: An understanding of how HCV causes B cell dysregulation could lead to improved treatments for HCV MC. Moreover, these studies could further our understanding of viral-induced autoimmunity and malignancy. ..
  45. Columbia-South Africa Training Program for Research on HIV-associated Malignanci
    Alfred I Neugut; Fiscal Year: 2013
    ....
  46. Cancer Risk: Advancing knowledge in systemic rheumatic disease
    Rosalind Ramsey-Goldman; Fiscal Year: 2013
    ....
  47. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2013
    ..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..
  48. Multi-functional Nanocarrier against Canine Lymphoma
    Kit S Lam; Fiscal Year: 2013
    ..These nanotherapeutics will be evaluated for their anti-tumor efficacies in transgenic mouse lymphoma model and in companion dogs with spontaneous lymphomas. ..
  49. A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
    Graham A Colditz; Fiscal Year: 2013
    ..To address these aims, we propose four research projects and five cores that form a cohesive, transdisciplinary center focused on research, training/career development, and dissemination. ..
  50. Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgk
    Mitchell S Cairo; Fiscal Year: 2012
    ....
  51. Models for cumulative spatial-temporal assessment of non-Hodgkin lymphoma risk
    DAVID CHARLES WHEELER; Fiscal Year: 2013
    ....
  52. BIOMEDICAL (BASIC)
    ANNECLAIRE DEROOS; Fiscal Year: 2009
    ..After carefully characterizing this pathway, these data will become a useful resource for future studies of NHL in the WHI. ..
  53. Reducing Complement Inhibition to Treat Leukemia and Lymphoma
    DARRICK ALBERT CARTER; Fiscal Year: 2013
    ....
  54. MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL
    Hao Wu; Fiscal Year: 2013
    ..abstract_text> ..
  55. Multiple Myeloma Consortium Study of Occupational Exposures and Family History
    Anneclaire J De Roos; Fiscal Year: 2013
    ....
  56. Quantitative SPECT for Targeted Radionuclide Therapy
    Eric C Frey; Fiscal Year: 2013
    ..These methods would provide substantial improvements in 3D dose estimates, and thus in the ability to predict and understand biological response and optimize therapeutic doses for TRT. ..
  57. Role of constitutive androstane receptor in cyclophosphamide-based chemotherapy
    Hongbing Wang; Fiscal Year: 2013
    ..Improved understanding of the underlying mechanism(s) associated with hCAR-mediated enhancement of the anticancer activity of CPA may ultimately benefit the development of new therapeutic strategies. ..
  58. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
    Edmund A Rossi; Fiscal Year: 2011
    ..The lessons learned from this project may eventually lead to the development of additional MAb-IFNa for therapy of a variety of hematopoeitic and solid tumors. ..
  59. Enhancing Information Dissemination on Health Disparities Research: A Database
    Bill Bowers; Fiscal Year: 2010
    ..We intend to complete this in a format to be ready for use and to be returned to NCMHD in total at the end of the grant period. ..
  60. Eating for Life: Dietary Behaviors Among Long Term Cancer Survivors
    Katherine Clegg Smith; Fiscal Year: 2012
    ..and history and survivorship identity with current dietary data from a sample of 60 long term survivors of non Hodgkin lymphoma, breast and prostate cancer...
  61. Molecular targets in diffuse large B cell lymphoma
    Sandeep Dave; Fiscal Year: 2013
    Diffuse large B cell lymphoma (DLBCL) is the most common form of non Hodgkin lymphoma, with an annual incidence of 25,000 in the United States and nearly 10,000 deaths per year attributable to the disease...
  62. Ecological and Health Consequences of the Vietnam War
    Linda Schwartz; Fiscal Year: 2001
    ..Protection Agency (EPA) as a "known carcinogen," the discussion of rare cancers, Soft Tissue Sarcomas, and Non Hodgkin Lymphoma and cancers of all sites combined will be a focal point of the program...
  63. Combined radio- and immunotherapy of aggressive NHL
    William A Wegener; Fiscal Year: 2013
    ....
  64. HAIR DYE USE AND RISK OF NONHODGKINS LYMPHOMA
    Tongzhang Zheng; Fiscal Year: 2000
    ..Statistical analyses will be performed using standard techniques to address the questions raised by the specific aims. ..
  65. Development of therapeutic monoclonal antibody to the bioactive lipid lysophospha
    Rosalia Matteo; Fiscal Year: 2009
    ..Discovering the major determinants in cancer progression for the development of more efficacious therapies is therefore extremely important to society. ..
  66. Molecular Epidemiology of non-Hodgkin Lymphoma Survival
    James R Cerhan; Fiscal Year: 2010
    ..Host genetics may also lead to a better understanding of NHL pathophysiology that could lead to new approaches to improve the survival of NHL patients. ..
  67. DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPT
    George Strickland; Fiscal Year: 2002
    ..abstract_text> ..
  68. DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPT
    George Strickland; Fiscal Year: 2004
    ..abstract_text> ..
  69. Vitamin D, alcohol, and risk of lymphomas in a prospective cohort of women
    ELLEN TING YEE CHANG; Fiscal Year: 2010
    ....
  70. Race-Specific Occupational Risk Factors for Cancer
    NATHANIEL BRIGGS; Fiscal Year: 2004
    ..abstract_text> ..
  71. PREVALENCE AND PATHOLOGIC BURDEN OF HTLV-II INFECTION
    Brian Hjelle; Fiscal Year: 1992
    ..The goal of this study is to define any potential of HTLV-II to induce lymphoid neoplasms in the HTLV-II-endemic populations...
  72. Outcomes of Curable Cancers in Vulnerable Populations
    Siran Koroukian; Fiscal Year: 2009
    ..We will examine survival outcomes by Medicaid status;and among Medicaid beneficiaries, survival and cure rates will be evaluated in the presence or absence of mental and/or physical comorbid conditions. ..
  73. STRUCTURES OF ANTIBIOTICS AND RELATED COMPOUNDS
    Robert Coates; Fiscal Year: 2003
    ....
  74. PATHOGENESIS OF H PYLORI INDUCED GASTRIC INFLAMMATION
    Richard Peek; Fiscal Year: 2000
    ..pylori virulence genes on cytokine production in vitro. ..
  75. PHASE I STUDY OF ANTICD20/STREPTAVIDIN
    Hazel Breitz; Fiscal Year: 2001
    ..These phase I studies will define schema and doses for a subsequent phase II study of PRIT using the fusion anti-CD20/streptavidin protein in patients with CD20+ non-Hodgkin's lymphoma. ..